Physician profile
Albert Bonebrake
NPI 1881636090
$1,625.73
in general payments reported to CMS, 2019-2025
10 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $70.46 · 2021: $337 · 2022: $339 · 2023: $297 · 2024: $202 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $369.38 | 2021-2023 | Myrisk |
| Eisai INC. | $296.34 | 2021-2025 | |
| Intuitive Surgical, INC. | $281.81 | 2019-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $181.61 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $176.13 | 2023-2024 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $170.34 | 2019-2022 | |
| Davol INC. | $134.56 | 2023 | |
| Conmed Corporation | $15.56 | 2024 | Airseal |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Bonebrake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.